Reports for APOTEX INC
Company Name APOTEX INC |
||
|---|---|---|
Totals |
||
Shortage reports |
3367 |
|
| Actual shortage: | 219 (7%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 341 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2025-01-23 | 2025-03-14 | 248489 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2025-03-07 | 2025-03-14 | 252148 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2019-03-13 | 2019-05-13 | 78536 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2019-03-13 | 2019-05-13 | 78541 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2022-12-16 | 2023-01-20 | 178742 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-02-23 | 2023-05-06 | 185459 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-03-02 | 2023-05-06 | 185942 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-06-16 | 2023-08-18 | 195063 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2021-04-23 | 2021-06-28 | 137962 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-06-04 | 2021-06-22 | 140420 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2021-06-25 | 2021-07-19 | 141537 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-06-13 | 2024-07-19 | 230489 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-09-12 | 2024-11-15 | 237375 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-10-31 | 2025-02-07 | 241688 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2018-02-26 | 2018-07-18 | 41142 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2018-03-27 | 2018-04-10 | 44111 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2018-05-31 | 2018-08-14 | 50961 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2018-08-09 | 2018-10-26 | 57799 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2018-11-30 | 2018-12-21 | 68228 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2018-11-30 | 2019-05-24 | 68231 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |